SHB 2152
SignedHouse
Cannabis/health facilities
Permitting the medical use of cannabis by qualifying patients in specified health care facilities.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill allows terminally ill patients in Washington to use medical cannabis in hospitals, nursing homes, and hospice facilities, under facility-specific policies that prioritize safety and dignity. It sets strict rules about how cannabis can be used, stored, and removed—while explicitly banning staff from administering it—and clarifies that federal drug scheduling alone cannot be used to prohibit use.
- Starting January 1, 2027, hospitals, nursing homes, and hospice centers must allow terminally ill patients to use medical cannabis on-site under the facility’s policy.
- Facilities must prohibit smoking or vaping of cannabis—even if that’s the patient’s usual method—and require alternative methods like edibles or tinctures.
- Patients (or their designated providers) must provide a valid medical cannabis authorization and are responsible for acquiring, storing, and removing unused cannabis.
- Medical cannabis must be stored in a locked container in the patient’s room or with the designated provider, and staff may not administer it.
- Policies must include rules against sharing cannabis, require documentation in medical records, and specify how leftover cannabis is disposed of after discharge.
- Facilities may pause compliance if federal agencies take enforcement action or issue prohibitions, but cannot ban cannabis solely because it’s a federal Schedule I drug.
Who is affected
- Terminally ill patients (qualifying patients) — Patients with a terminal illness who qualify under state law and wish to use medical cannabis for symptom relief or comfort while receiving care in a hospital, nursing home, or hospice facility.
- Designated providers and family caregivers — Families and caregivers who assist terminally ill patients with acquiring, storing, and administering medical cannabis, and who may need to remove unused product upon discharge.
- Health care facilities (hospitals, nursing homes, hospices) — Hospitals, nursing homes, and hospice centers must develop and implement policies to allow medical cannabis use under strict conditions, while ensuring staff do not administer it.
- Health care professionals and facility staff — Staff such as nurses, physicians, and pharmacists are prohibited from handling or administering medical cannabis, even if requested by the patient.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Explicitly affirms terminally ill patients’ right to use medical cannabis for comfort and symptom relief in institutional settings—addressing a gap in care access and supporting patient autonomy and dignity at end-of-life.
HealthcarePeopleRef: Sec. 1(2)(a), Sec. 2(1)Prevents facilities from banning cannabis solely due to federal Schedule I status, protecting patients’ access despite federal prohibition and reinforcing state sovereignty over medical decisions for qualifying patients.
Rights & LibertiesPeopleRef: Sec. 2(4)(b)Requires facilities to integrate medical cannabis into medical records and secure storage protocols—enhancing safety, transparency, and continuity of care for patients using cannabis alongside other medications.
HealthcarePeopleRef: Sec. 2(1)(c), (d), (e)Prohibition on sharing cannabis between patients reduces risk of diversion, misuse, or accidental ingestion—supporting facility safety without requiring staff involvement.
Public SafetyPeopleRef: Sec. 2(1)(g)Excludes emergency departments from the requirement, preserving clinical discretion in acute care where rapid sedation or pain management may conflict with cannabis use—balancing patient access with urgent medical needs.
HealthcarePeopleRef: Sec. 2(2)
Potential Concerns (5)
Shifts logistical and financial burden of acquiring, storing, and removing medical cannabis onto patients and families—potentially increasing out-of-pocket costs and time burden during a vulnerable period.
HealthcarePeopleRef: Sec. 2(1)(d), (e), (h)Prohibition on smoking/vaping—even if it is the patient’s preferred and most effective method—may reduce symptom relief efficacy for patients who rely on rapid-acting delivery, potentially worsening comfort and quality of life.
HealthcarePeopleRef: Sec. 2(1)(a)Facilities may suspend compliance if federal enforcement occurs, creating uncertainty and inconsistent access across facilities and over time, especially in a politically volatile federal cannabis enforcement climate.
HealthcareLean peopleRef: Sec. 2(4)(a)Bar on staff administration—even when a patient is physically unable to self-administer—may leave some terminally ill patients unable to use cannabis at all, undermining the bill’s stated dignity and comfort goals.
HealthcareLean peopleRef: Sec. 2(1)(f)Ambiguity around disposal of unused cannabis may lead to inconsistent or wasteful practices, and may cause distress if patients feel pressured to discard unused product before discharge due to unclear or overly strict facility policies.
HealthcareLean peopleRef: Sec. 2(1)(h)
Who Is Most Affected
Terminally ill patients gain formal recognition of their right to use medical cannabis for comfort in institutional settings, but may face barriers if unable to self-administer or afford alternative delivery methods (e.g., tinctures, edibles).
Caregivers gain legal authorization to assist with acquisition and storage, but face added responsibility and potential liability if cannabis is mishandled or not removed per policy—especially burdensome for low-income or time-constrained families.
Facilities gain legal clarity to develop policies without fear of licensing penalties, but must invest staff time in policy development, training, and documentation—costs likely absorbed by larger systems, while smaller facilities may struggle with compliance.
Clinicians and nurses avoid legal risk by not administering cannabis, but may feel ethically constrained when patients request help with a treatment that could improve their comfort—especially if unable to self-administer.
Cannabis dispensaries and specialty producers may see increased demand for non-smoked products (e.g., tinctures, capsules), but lack access to hospital procurement channels—limiting direct commercial benefit.